Macrophage Activation Marker Soluble Cd163 Is A Dynamic Marker Of Liver Fibrogenesis In Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
Anna Lidofsky,Jacinta A Holmes,Eoin R Feeney,Annie J Kruger,Shadi Salloum,Hui Zheng,Isabel S Seguin,Akif Altinbas,Ricard Masia,Kathleen E Corey,Jenna L Gustafson,Esperance A Schaefer,Peter W Hunt,Steven Deeks,Ma Somsouk,Kara W Chew,Raymond T Chung,Nadia Alatrakchi
DOI: https://doi.org/10.1093/infdis/jiy331
2018-01-01
Abstract:Background. Coinfection with human immunodeficiency virus (HIV) accelerates hepatitis C virus (HCV)-related liver fibrosis. Macrophages are triggered during both viral infections and are critical in liver inflammation/fibrogenesis. Liver fibrosis strongly associates with serum soluble CD163 (sCD163, a macrophage activation marker); comprehensive evaluation in HIV/HCV coinfection is lacking.Methods. We retrospectively analyzed sCD163 (enzyme-linked immunosorbent assay) and hepatic CD163 (immunofluorescent CD163/CD68 costaining) in patients infected with HIV/HCV, HCV, or HIV, pre- and post-antiviral therapy.Results. sCD163 was significantly higher in HIV/HCV compared to either monoinfection, and decreased following successful antiviral therapy, although did not fully normalize. In HIV/HCV, sCD163 was associated with necroinflammation, Ishak fibrosis scores, and noninvasive fibrosis scores. We observed a novel trend whereby sCD163 levels progressively increase with increasing Ishak fibrosis score, peaking at stage 4, above which levels plateaued. Periportal CD163(+) macrophage frequency was also higher with increasing fibrosis score. When stratified by fibrosis stage, sCD163 levels were higher in HIV/HCV than HCV but only in individuals with mild to moderate fibrosis.Conclusions. In HIV/HCV, increasing sCD163 levels accompanied periportal CD163(+) macrophage enrichment in mild to moderate fibrosis, but not in established cirrhosis, suggesting that sCD163 is a dynamic biomarker of fibrogenesis rather than accumulated fibrosis. Our findings implicate HIV-related macrophage activation in accelerated fibrosis progression in HIV/HCV coinfection.